JPRN-UMIN000019828已完成1 期
A phase I study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin - A phase I study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin (MODURATE study) MODURATE study
Pharma Valley Center0 个研究点目标入组 21 人开始时间: 2015年12月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Serious illness such as brain metastasis, systemic infection or gastrointestinal bleeding. 2) Medical treatment such as major surgery within 4 weeks, systemic chemotherapy within 2 weeks. 3) Adverse events due to prior chemotherapy 4) Administration of blood transfusion or G-CSF within 2 weeks 5) Severe pulmonaly disorder 6) Thromboembolism (grade3 or higher) within 6 months 7) Inappropriate for the study in the opinion of the investigator
研究者
相似试验
已完成
1 期
A phaseI/II study of irinotecan with bevacizumab as second line treatment of elderly patients with metastatic colorectal cancer.colorectal cancerJPRN-UMIN000009911Tsuchiura kyodo general hospital25
已完成
2 期
Phase II study of bevacizumab and irinotecan as second-line therapy in patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumabJPRN-UMIN000005228Tokyo Women's Medical University33
已完成
2 期
Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer.Metastatic colorectal cancer.JPRN-UMIN000008947Epidemiological and Clinical research Information Network (ECRIN)40
招募中
不适用
Phase 2 study of bevacizumab and irinotecan as second-line therapy in patients with advanced colorectal cancer previously treated with oxaliplatin and bavacizumabadvanced colorectal cancerJPRN-UMIN000007065Toyama Prefectural Central Hospital Department of Gastroenterology33
已完成
2 期
A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.colorectal cancerJPRN-UMIN000009910Tsuchiura kyodo general hospital25